Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for a quick audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.

Take a brief audio tour around Scrip's Five Must-Know Things, in this episode covering key developments in the business week ended 11 September 2020. 

In focus this time are a high-profile pause in a closely-watched coronavirus vaccine trial, one CEO's views on the pricing of COVID-19 interventions, a big Chinese oncology deal, promising results in asthma and an update on the fast-evolving migraine market.

Stories mentioned in this episode:

(Also see "AZ Exercises Caution With COVID Vaccine Safety Pause As Questions Remain Over Vector" - Scrip, 9 Sep, 2020.)

(Also see "Merck CEO Stresses Need For ‘Fair Return’ On COVID-19 Interventions" - Scrip, 7 Sep, 2020.)

(Also see "$2bn AbbVie Deal Puts I-Mab On Global Immuno-Oncology Map" - Scrip, 4 Sep, 2020.)

(Also see "Sanofi Showcases Long-Term Benefits Of Dupixent For Severe Asthma" - Scrip, 8 Sep, 2020.)

(Also see "Migraine Market Update: CGRP Inhibitors Slowly Gain Ground" - Scrip, 7 Sep, 2020.)


Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts